Inovio Pharmaceuticals Inc.

(NASDAQ: INO) Trade

By |

Equities News

Company chart and information is provided by TradingView based on 15-minute-delayed data.


Inovio Pharmaceuticals Inc.

Profile

Inovio is taking immunotherapy to the next level in the fight against cancer and infectious diseases. We are the only immunotherapy company that has reported generating T cells in vivo in high quantity that are fully functional and whose killing capacity correlates with relevant clinical outcomes with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include MedImmune, Regeneron Pharmaceuticals, Genentech, GeneOne Life Science, Plumbline Life Sciences, ApolloBio Corporation, The Wistar Institute, Laval University, University of Pennsylvania, Drexel University, DARPA, NIH, HIV Vaccines Trial Network, National Cancer Institute, and U.S. Military HIV Research Program. For more information, visit www.inovio.com.

Contact Information

Website: www.inovio.com
Email: ben.matone@inovio.com
Main Phone: +1 267 440-4200
Address: 660 West Germantown Pike
Address 2: Suite 110
State: PA
City / Town: Plymouth Meeting
Country: US
Postal Code: 19462

Issuer Information

Exchange: NGS
CEO: J. Joseph Kim
Employees: 262
Issuer Type: CS - Common Stock
Sector/Industry: Cyclical
NAICS: Biological Product (except Diagnostic) Manufacturing(325414)

Equities News

View More
(%)
Company data no longer available
Last Price N/A Change $ N/A Change % N/A Tick N/A
Bid N/A Bid Size N/A Ask N/A Ask Size N/A
Open N/A High N/A Low N/A Prev Close N/A
Last Trade Volume N/A 52 Wk Hi N/A 52 Wk Low N/A
Market Cap N/A Ex-Div Date N/A Div Rate N/A Yield N/A
Shares N/A EPS (TTM) N/A PE Ratio N/A Exchange N/A